207results about How to "Lower titer" patented technology

Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.

The present invention relates generally to binding agents useful in the selective depletion of T cells in vivo. More specifically, the invention relates to ICOS-binding agents which once bound to ICOS expressed on the surface of cells, in particular ICOS-bearing activated T cells, result in the in vivo depletion of cells to which they are bound. Methods of treating T cell related diseases using said ICOS-binding agents, and pharmaceutical compositions comprising said ICOS-binding agents, a method of identifying an ICOS-binding agent, and monoclonal anti-ICOS antibodies capable of eliminating cells in vivo which express ICOS on their surface are also provided.

The present invention provides compositions and methods for reducing the immunogenicity and increasing the circulating half-life of therapeutic proteins such as Factor VIII. The compositions comprise lipidic structures such as liposomes, micelles and cochleates comprising a negatively charged lipid and polyethylene glycol derivatized phosphatidyl ethanolamine.

The invention relates to duck plague yolk antibody freeze-dried powder, which comprises the following components in percentage by weight: 87 to 90 percent of duck plague yolk antibody, 0.8 to 1.0 percent of octanoic acid, 0.2 to 0.3 percent of formaldehyde, 0.01 to 0.02 percent of thimerosal, 3 to 4 percent of glucose, 1 to 2 percent of sorbitol, 2 to 3 percent of glycine and 2 to 3 percent of mannitol. The freeze-dried powder has the advantages of long storage time, quick dissolution, high antibody valence and high bioactivity, and the purity of the antibody of the freeze-dried powder is higher than that of the conventional product in market. The invention also discloses a preparation method for the duck plague yolk antibody freeze-dried powder. The preparation method comprises the following steps of: separating strains to prepare vaccines, immunizing healthy ducks to obtain high-immunity eggs, performing sterilization, acidification, octanoic acid treatment, refining, extraction, purification, preparation, freeze drying and the like on the high-immunity eggs, and thus obtaining the duck plague high-immunity yolk antibody freeze-dried powder. According to the preparation method, yolk liquid is heated by using the temperature of pasteurization during acidification and water treatment, so that a sterilization effect is achieved, and the recovery rate of the antibody and the clarity of the solution during acidification can be improved at the same time; and the prepared yolk antibody has the advantages of high bioactivity, long storage time, retarded valence reducing speed and the like.

This invention is preparation procedure of the yolk antibody of high biological activity, belonging to the field of bioproduct and industrialized isolation technique. In this invention, we adopt the natural macromolecule gel high -extractive technique and hyperfiltration to extract the yolk-antibody of high biological activity from yolk at an industrialized level, annual output is upto 10 ton. the yolk-antibody content is about 30%-50%, meanwhile we could obtain some by-products like albumen powder, yolk powder, egg oil, vitellin and so on. In the invention high technology like bioimmunology and membrane separation is adopted. The invention is high-tech, high-usage, highly-automated and typical of green food and environmental-friendly.

The invention provides a screening method of a sgRNA (small guide ribonucleic acid) efficient action target based on a CRISPR-Cas13d (clustered red regularly interspaced short palindromic repeat) system and application, and particularly application in RNA virus knockdown. According to the screening method, two expression read frame sequences ORF4 and ORF5 of a PRRSV are respectively fused with a carbon end of a mCherry gene through a mCherry fluorescence report gene, a fluorescence report system for screening sgRNA efficient action targets of the CRISPR-Cas13d system is established, and by virtue of the property that mRNA is efficiently cut by CRISPR-Cas13d, rapid screening of sgRNAs with high efficiency is implemented. Additionally, PRRSV-GFP recombinant viruses are efficiently degraded by using the screened efficient targetedly combined sgRNA based on the CRISPR-Cas13d system. The RNA virus knockdown method provided by the invention has the advantages of being high in efficiency, high in precision and low in target missing rate.

The invention relates to a pig pseudorabies virus natural low-virulent C strain and a heatproof preservation method thereof. The microbe collection registry number of the strain is CCTCC NO: V201114. According to the invention, various cryoprotectant substrates are mixed and blended according to a certain ratio; the cryoprotectants are respectively subject to aseptic processing; cryoprotectant components that can be subject to high-pressure sterilization are dissolved in bi-distilled water, and are sterilized for 15-30min under a temperature of 108-121 DEG C; cryoprotectant components that can not be subject to high-pressure sterilization are dissolved in bi-distilled water according to a certain formula, and are sterilized by using a filter membrane with a size of 0.22mum; all the cryoprotectant components are then mixed into a heatproof cryoprotectant; the heatproof cryoprotectant is mixed with a pseudorabies virus liquid according to a ratio of 1:1-1.2; and the mixture is lyophilized with a corresponding lyophilization curve. Compared to prior arts, the C strain provided by the invention has good stability. In a fifth generation animal of continuous back-procreation, the genetic sequence is stable, and no mutation is found. Therefore, the strain provided by the invention provides a good resource for the researches of pig pseudorabies low-virulent vaccines. The strain can bepreserved for 24 months under a temperature of 2-8 DEG C, and the virus titer is reduced by no more than 1 titer.

The invention discloses a process for preparing straight-through 6-aminopenicillanic acid, which comprises the following steps: a, filtering and acidizing penicillin fermentation solution, extracting the penicillin fermentation solution by using butanol, and concentrating and decoloring the extract to obtain butyl ester extracting solution of penicillin; b, back extracting the butyl ester extracting solution of the penicillin by using alkali solution to obtain brine solution of penicillin (heavy phase or RB for short); c, continuously injecting the brine solution of the penicillin into a degreasing tower in a vacuum pressure reduction state to convert the butyl ester into a gas phase from the brine solution of the penicillin, discharging the degreased brine solution of the penicillin out of a pressure reduction system from the bottom of the tower to a storage tank with a cooling device, and cooling the degreased brine solution of the penicillin for later use; and d, performing enzymatic conversion on the degreased brine solution of the penicillin, then adding 6-APA crystal seeds into the solution, growing the crystals, crystallizing the solution, and drying the crystals.

The invention provides a pretreatment method capable of removing an antibiotic in antibiotic pharmaceutical wastewater and an antibiotic pharmaceutical wastewater treatment method. The pretreatment method comprises the steps of adding a solid acid to the antibiotic pharmaceutical wastewater and carrying out hydrolysis treatment on residual antibiotic in the antibiotic pharmaceutical wastewater. According to the method, the concentration of the antibiotic in the antibiotic pharmaceutical wastewater can be significantly reduced, an active functional group in an antibiotic molecule is hydrolyzed and destroyed, inhibition of the high-concentration antibiotic on microorganisms is reduced, the difficulty of subsequent biochemical wastewater treatment is reduced, drug-resistant bacteria and drug-resistant genes in subsequent biochemical treatment are reduced, and the treated antibiotic pharmaceutical wastewater can be connected to the subsequent biochemical treatment process for treatment.

Provided herein are immunization regimens for inducing an immune response (e.g., an antibody response) against influenza virus. In specific aspects, the immunization regimens involve the administration of a chimeric hemagglutinin (HA), a headless HA or another influenza virus stem domain based construct (e.g., the HA stem domain or a fragment thereof) to a subject. In certain aspects, the immunization regimens also involve the administration of an influenza virus neuraminidase immunogen.

The invention discloses a lentiviral vector suitable for gene therapy of thalassemia and sickle anemia. The lentiviral vector comprises a beta globin expression cassette; the expression cassette comprises a micro-locus control area, a gene sequence of a beta globin, a promoter sequence of a flank of the upstream of the gene sequence of the beta globin, and a flanking sequence of the downstream ofthe gene sequence of the beta globin; the micro-locus control area is a micro-control element which is screened out from the locus control area of beta globin 16kb and does not contain an HS1 area. Compared with the prior art, the screened beta globin expression cassette has both efficiency and specificity, and does not cause reduction of lentivirus titer; a screened insulator sequence which comesfrom foamy virus and is only 36 bp does not contain a hidden RNA splicing signal, and has the functions of maintaining gene expression and preventing gene activation in a region where the insulator sequence is located; the lentiviral vector can be used for gene therapy of thalassemia and sickle anemia.

The invention provides a cell-factory-based measles virus stock solution and a measles-series attenuated live vaccine preparation. A preparation method of the measles virus stock solution includes selecting SPF chick-embryo cells, and adding cell culture fluid to prepare cell suspension liquid, and adding the cell suspension liquid into a cell factory; inoculating the cell factory with working seeds of measles viruses and the cell suspension liquid according to the ratio of the working seeds to the cell suspension liquid being (0.005-0.05):1, and standing and cultivating the cell factory at the temperature of 33+/-1 DEG C for 3-4 days, pouring out archeocyte culture fluid, and replacing with fresh cell growth liquid for continuous cultivation; during cytopathy, collecting single measles virus liquid step by step. In an equal production scale, the batch number of cell dissociation is reduced, and the high-titer measles virus liquid is obtained, so that quality uniformity of measles-series vaccine products is improved effectively, and product yield is increased.